Cardiotoxicity in Breast Cancer Patients

StatusRecruiting
PhasePhase 4
Started

Record status This record was last updated September 22, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 2025 to Jun 2026v4
  2. Trial status: Not Yet Recruiting to Recruitingv3 Show 6 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Jul 2025 to Oct 2025
    • Study completion date: Oct 2025 to Dec 2025
    • Start date changed from estimate of Jul 2024 to Sep 10, 2024
    • Secondary endpoints: 2 to 1
    • Study title shortened, about 9 words
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Helwan University
19 trials monitored
See 2 trials at risk
Breast Cancer
5,481 trials monitored
See 311 trials at risk
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug. Aim of the study: Evaluate cardioprotective effect and safety of dapagliflozin against anthracyclines-induced cardiotoxicity. The main questions it aims to answer are: 1. Does the drug lower the cardiotoxicity which induced by anthracyclines? 2. What medical problems do participants have when taking dapagliflozin drug? Treatment 1. Anthracyclines by 4 cycles included doxorubicin 50-60 mg/m2 with cyclophosphamide 600 mg as a combination or epirubicin 90-100 mg/m2 with cyclophosphamide 600 mg as a combination. 2. Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.
Trial Details
NCT Number NCT06491680
Lead Sponsor Helwan University
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov